[{"question": "A 78-year-old woman with a history of type 2 diabetes treated with oral antidiabetic agents, HBP in treatment with beta-blockers and ACE inhibitors, and congestive heart failure grade 1 of NYHA, with a LVEF of 48%, and currently asymptomatic. Functional state: ECOG 0. History of 2 years of evolution of small lumps in the neck. Cervical adenopathy biopsy: grade 2 follicular lymphoma. Extension study: Hb 12 gr / dL, Leucocytes 6,900 / microL (Neutrophils 60%, Lymphocytes 27%, Monocytes 6%, Eosinophils 4%, Basophils 4%) Platelets 220,000 / microL. MO: infiltrated by follicular lymphoma. Creatinine 1.5 mg / dL, LDH 235 U / L, Beta2 microglobulin 2.1 microg / mL. TAC: adenopathies less than 3 cm in cervical, axillary, retroperitoneal, iliac and inguinal territories; Normal liver and spleen. Which of the following treatments is the most appropriate?", "correct_answer": "Do not try and watch (wait and see).", "correct_idx": 2, "options": ["A)Rituximab-CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone).", "B)Rituximab-CVP (Cyclophosphamide, Vincristine, Prednisone).", "C)Do not try and watch (wait and see).", "D)Rituximab-Bendamustine"], "prompt": "A 78-year-old woman with a history of type 2 diabetes treated with oral antidiabetic agents, HBP in treatment with beta-blockers and ACE inhibitors, and congestive heart failure grade 1 of NYHA, with a LVEF of 48%, and currently asymptomatic. Functional state: ECOG 0. History of 2 years of evolution of small lumps in the neck. Cervical adenopathy biopsy: grade 2 follicular lymphoma. Extension study: Hb 12 gr / dL, Leucocytes 6,900 / microL (Neutrophils 60%, Lymphocytes 27%, Monocytes 6%, Eosinophils 4%, Basophils 4%) Platelets 220,000 / microL. MO: infiltrated by follicular lymphoma. Creatinine 1.5 mg / dL, LDH 235 U / L, Beta2 microglobulin 2.1 microg / mL. TAC: adenopathies less than 3 cm in cervical, axillary, retroperitoneal, iliac and inguinal territories; Normal liver and spleen. Which of the following treatments is the most appropriate?A)Rituximab-CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone).\nB)Rituximab-CVP (Cyclophosphamide, Vincristine, Prednisone).\nC)Do not try and watch (wait and see).\nD)Rituximab-Bendamustine", "subject_name": "medicine", "output0": "The most appropriate treatment for this patient is Rituximab-CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) because the patient has follicular lymphoma, and Rituximab is an anti-CD20 monoclonal antibody that specifically targets B cells, which are the cancer cells in this type of lymphoma. CHOP is a common chemotherapy regimen used to treat follicular lymphoma, and it is effective at inducing remission and improving survival.\n\n", "output1": "The most appropriate treatment for this patient with follicular lymphoma and cervical adenopathy is Rituximab-CVP (Cyclophosphamide, Vincristine, Prednisone). This treatment is effective in managing follicular lymphoma and has a favorable risk-benefit profile for patients with this diagnosis. Additionally, the patient's age and comorbidities make more intensive treatments such as chemotherapy with Rituximab-CHOP less appropriate.\n\n", "output2": "The patient has a low-grade lymphoma, and the clinical presentation is asymptomatic. Therefore, the most appropriate treatment is to monitor the patient's condition closely and only intervene if the disease progresses or if there are any symptoms.\n\n", "output3": "The most appropriate treatment for this patient with follicular lymphoma and cervical adenopathy would be Rituximab-Bendamustine. This combination of rituximab, an anti-CD20 monoclonal antibody, and bendamustine, an alkylating agent, is a chemoimmunotherapy regimen that has been shown to be effective in the treatment of follicular lymphoma, particularly in patients with indolent disease.\n\n"}, {"question": "The characteristic of a water-insoluble substance most important in governing its diffusibility through a cell membrane is its.", "correct_answer": "Lipid solubility", "correct_idx": 3, "options": ["A)Hydrated diameter", "B)Molecular weight", "C)Electrical charge", "D)Lipid solubility"], "prompt": "The characteristic of a water-insoluble substance most important in governing its diffusibility through a cell membrane is its.A)Hydrated diameter\nB)Molecular weight\nC)Electrical charge\nD)Lipid solubility", "subject_name": "Unknown", "output0": "The hydrated diameter of a substance is the diameter of the molecule when it is fully hydrated, which is the state in which it is most likely to diffuse through a cell membrane. This is because the larger the molecule, the more difficult it is for it to diffuse through the membrane.\n\n", "output1": "The molecular weight of a substance is a major determinant of its diffusibility through a cell membrane. Larger molecules have a harder time diffusing through the membrane, while smaller molecules can diffuse more easily.\n\n", "output2": "The electrical charge of a substance is the most important factor in determining its diffusibility through a cell membrane. This is because the electrical charge of a substance can interact with the electrical charge of the cell membrane, which can affect its ability to diffuse through the membrane.\n\n", "output3": "The characteristic of a water-insoluble substance that most governs its diffusibility through a cell membrane is its lipid solubility. This is because lipid-soluble molecules can diffuse easily through the lipid bilayer of the cell membrane, while hydrophilic (water-soluble) molecules have a much harder time doing so.\n\n"}, {"question": "A properly designed rest on lingual surface of a canine is preferred to a rest on incisal surface because:", "correct_answer": "Less Leverage is exerted against the tooth by Lingual rest", "correct_idx": 0, "options": ["A)Less Leverage is exerted against the tooth by Lingual rest", "B)Enamel is thicker on lingual surface", "C)Visibility and access is better on lingual surface", "D)The cingulum of canine produces a naturalsurface for recess"], "prompt": "A properly designed rest on lingual surface of a canine is preferred to a rest on incisal surface because:A)Less Leverage is exerted against the tooth by Lingual rest\nB)Enamel is thicker on lingual surface\nC)Visibility and access is better on lingual surface\nD)The cingulum of canine produces a naturalsurface for recess", "subject_name": "Dental", "output0": "A properly designed rest on the lingual surface of a canine exerts less leverage against the tooth compared to a rest on the incisal surface. This is because the lingual surface is more parallel to the long axis of the tooth, which reduces the amount of force required to move the tooth. Additionally, the lingual surface is typically flatter and smoother than the incisal surface, which can provide a more stable foundation for the rest.\n\n", "output1": "Enamel is thicker on the lingual surface of the canine tooth than on the incisal surface. This is because the lingual surface is subject to less wear and tear than the incisal surface, which is exposed to more forces during chewing and biting.\n\n", "output2": "A properly designed rest on the lingual surface of a canine provides better visibility and access for the clinician, making it easier to place and adjust the rest. Additionally, the lingual surface is more accessible for cleaning and maintenance.\n\n", "output3": "A proper rest on the lingual surface of a canine tooth is preferred because the cingulum of the canine produces a natural surface for recess. This allows for a more secure and comfortable restoration.\n\n"}, {"question": "Which of following is not a tumor suppressor gene?", "correct_answer": "c-erbB1", "correct_idx": 3, "options": ["A)pRb", "B)FHIT", "C)PTCH", "D)c-erbB1"], "prompt": "Which of following is not a tumor suppressor gene?A)pRb\nB)FHIT\nC)PTCH\nD)c-erbB1", "subject_name": "Pathology", "output0": "pRb is not a tumor suppressor gene. It is a protein that regulates the cell cycle and is involved in the development of many types of cancer. The other options, FHIT, PTCH, and c-erbB1, are all tumor suppressor genes.\n\n", "output1": "FHIT is a gene that encodes for a protein involved in the repair of DNA damage, but it is not a tumor suppressor gene. The other options, pRb, PTCH, and c-erbB1, are all tumor suppressor genes.\n\n", "output2": "PTCH is not a tumor suppressor gene. It is a gene that encodes for a protein called platelet-derived growth factor receptor beta (PDGFR\u03b2), which is involved in the regulation of cell growth and differentiation. The other options, pRb, FHIT, and c-erbB1, are all known to be tumor suppressor genes.\n\n", "output3": "c-erbB1 is a gene that encodes a protein involved in cell growth and differentiation, but it is not a tumor suppressor gene. The other options, pRb, FHIT, and PTCH, are all known to be tumor suppressor genes.\n\n"}, {"question": "Which of the following is not used in osteoporosis?", "correct_answer": "Milnacipran", "correct_idx": 0, "options": ["A)Milnacipran", "B)PTH", "C)Strontium ranelate", "D)Denosumab"], "prompt": "Which of the following is not used in osteoporosis?A)Milnacipran\nB)PTH\nC)Strontium ranelate\nD)Denosumab", "subject_name": "Pharmacology", "output0": "Milnacipran is not used in the treatment of osteoporosis. It is an antidepressant medication that is used to treat depression and anxiety disorders.\n\n", "output1": "PTH (Parathyroid Hormone) is not used in the treatment of osteoporosis. The other options, Milnacipran, Strontium ranelate, and Denosumab, are all medications that have been approved for the treatment of osteoporosis.\n\n", "output2": "Strontium ranelate is not used in the treatment of osteoporosis. It is used to prevent bone loss in patients with osteoporosis, but it is not a treatment for osteoporosis itself. The other options, Milnacipran, PTH, and Denosumab, are all used to treat osteoporosis.\n\n", "output3": "Denosumab is not used in the treatment of osteoporosis. The other options, Milnacipran, PTH, and Strontium ranelate, are all used to treat osteoporosis.\n\n"}, {"question": "The shape of the occlusal surface of the permanent maxillary first molar is:", "correct_answer": "Rhomboidal", "correct_idx": 3, "options": ["A)Oval", "B)Trapezoidal", "C)Triangular", "D)Rhomboidal"], "prompt": "The shape of the occlusal surface of the permanent maxillary first molar is:A)Oval\nB)Trapezoidal\nC)Triangular\nD)Rhomboidal", "subject_name": "Dental", "output0": "The occlusal surface of the permanent maxillary first molar is oval in shape. This shape allows for the best possible fit between the maxillary and mandibular teeth, promoting proper chewing function and preventing issues such as overbites or underbites.\n\n", "output1": "The occlusal surface of the permanent maxillary first molar is trapezoidal in shape because it is wider in the middle than at the edges. This shape allows for a more efficient mastication and grinding of food.\n\n", "output2": "The occlusal surface of the permanent maxillary first molar is triangular in shape because it is formed by the intersection of three surfaces: the mesio-distal surface, the buccal surface, and the lingual surface. This shape allows for efficient mastication and grinding of food.\n\n", "output3": "The occlusal surface of the permanent maxillary first molar is rhomboidal in shape. This shape allows for a broad surface area for grinding and crushing food, and also provides a stable platform for the teeth to function properly.\n\n"}, {"question": "Raspberry tumor is seen in", "correct_answer": "Umbilical adenoma", "correct_idx": 2, "options": ["A)Umbilical fistula", "B)Meckel's diveiculum", "C)Umbilical adenoma", "D)Umbilical granuloma"], "prompt": "Raspberry tumor is seen inA)Umbilical fistula\nB)Meckel's diveiculum\nC)Umbilical adenoma\nD)Umbilical granuloma", "subject_name": "Surgery", "output0": "The correct answer is A)Umbilical fistula because Raspberry tumor is a rare congenital malformation that is often associated with umbilical fistula.\n\n", "output1": "Meckel's diverticulum is a type of congenital anomaly in which a small pouch forms in the wall of the small intestine. Raspberry tumor is a rare condition that develops in Meckel's diverticulum and is characterized by the formation of a tumor that resembles a raspberry. Therefore, option B is the correct answer.\n\n", "output2": "Umbilical adenoma, also known as umbilical tumor, is a benign tumor that occurs in the umbilical cord and is often associated with the presence of a raspberry-like mass. It is the most common type of umbilical tumor and is typically seen in older children and adolescents.\n\n", "output3": "Raspberry tumor is a type of umbilical granuloma. It is a benign tumor that occurs near the umbilical cord and is typically seen in older children. It is not associated with any other congenital anomalies or birth defects.\n\n"}, {"question": "True about colchicines is/are?", "correct_answer": "All of the above", "correct_idx": 3, "options": ["A)Acts by neutrophil recruitment", "B)Causes metaphase arrest", "C)Useful in urate-lowering therapy", "D)All of the above"], "prompt": "True about colchicines is/are?A)Acts by neutrophil recruitment\nB)Causes metaphase arrest\nC)Useful in urate-lowering therapy\nD)All of the above", "subject_name": "Pharmacology", "output0": "Colchicine acts by recruiting neutrophils to the site of inflammation, where they can help to clear the inflammatory response.\n\n", "output1": "Colchicines acts by causing metaphase arrest, which is a temporary halt in the cell cycle. This allows the cell to recover from damage and repair itself. It is useful in urate-lowering therapy because it can help reduce the levels of uric acid in the blood.\n\n", "output2": "Colchicines are used in urate-lowering therapy because they inhibit the activity of the enzyme fibroblast growth factor-2 (FGF-2), which is involved in the formation of uric acid crystals. By inhibiting the activity of FGF-2, colchicines can help to reduce the levels of uric acid in the blood and prevent the formation of new uric acid crystals.\n\n", "output3": "Colchicine is a medication that is used to treat gout, a condition that causes inflammation and pain in the joints. It works by neutrophil recruitment, causing metaphase arrest, and is useful in urate-lowering therapy. Therefore, all of the above statements are true about colchicines.\n\n"}, {"question": "What characterizes lactate dehydrogenase in lactic acid fermentation ?:", "correct_answer": "Consume NADH and produce NAD +.", "correct_idx": 2, "options": ["A)Have acetyl-CoA as substrate.", "B)Release CO2.", "C)Consume NADH and produce NAD +.", "D)Allow glycolysis to continue under aerobic conditions."], "prompt": "What characterizes lactate dehydrogenase in lactic acid fermentation ?:A)Have acetyl-CoA as substrate.\nB)Release CO2.\nC)Consume NADH and produce NAD +.\nD)Allow glycolysis to continue under aerobic conditions.", "subject_name": "biology", "output0": "Lactate dehydrogenase is an enzyme that plays a key role in lactic acid fermentation. It catalyzes the conversion of lactate to pyruvate, and it has acetyl-CoA as its substrate.\n\n", "output1": "Lactic acid fermentation is a process that occurs in the absence of oxygen, and it is characterized by the conversion of glucose to lactic acid. One of the byproducts of this process is the release of CO2.\n\n", "output2": "Lactate dehydrogenase (LDH) is an enzyme that plays a key role in lactic acid fermentation. LDH catalyzes the conversion of lactate to pyruvate, which is the final product of glycolysis. In this process, NADH is consumed and NAD + is produced.\n\n", "output3": "Lactate dehydrogenase (LDH) is an enzyme that plays a key role in lactic acid fermentation. It catalyzes the conversion of lactate to pyruvate, which allows glycolysis to continue under aerobic conditions. This means that LDH enables the cell to continue producing energy through glycolysis, even in the absence of oxygen.\n\n"}, {"question": "A 40-year-old woman schedules an appointment for a routine medical check-up. She admits to being careless about her health, but is motivated to improve. She is working with a personal trainer at the gym and is following a weight reduction diet plan. Despite a 20 kg (44 lb) weight loss over the last year, she still feels that she is fat. She was a frequent binge drinker, but now she has reduced her alcohol consumption to a single glass of wine with dinner and an occasional beer on the weekend. She also has a 15 pack-year smoking history, but quit 6 months ago after she developed a cough and shortness of breath that later improved. She admits to trying various recreational drugs in the past. On her last visit, she was started on rosuvastatin for an elevated cholesterol level. She is sexually active with her partner and they have 2 children. She is uncertain about her family history as she was raised in foster care. The vital signs include: pulse 80/min, respirations 16/min, and blood pressure 122/80 mm Hg. The physical examination reveals a visibly overweight woman with a body mass index (BMI) of 34 kg/m2. The remainder of the examination yields no significant findings. An electrocardiogram (ECG) and chest X-ray are both normal. Lab tests show the following:\nSerum glucose (fasting) 95 mg/dL\n    Serum electrolytes:\nSodium 140 mEq/L\nPotassium 3.8 mEq/L\nChloride 101 mEq/L\nSerum creatinine 0.8 mg/dL\nBlood urea nitrogen 10 mg/dL\nCholesterol, total 180 mg/dL\nHDL-cholesterol 42 mg/dL\nLDL-cholesterol 70 mg/dL\nTriglycerides 365 mg/dL\n    Urinalysis:  \nGlucose negative\nKetones negative\nLeucocytes negative\nNitrites negative\nRBC negative\nCasts negative\nWhich medication would most likely further improve her lipid profile?", "correct_answer": "Fenofibrate", "correct_idx": 2, "options": ["A)Niacin", "B)Orlistat", "C)Fenofibrate", "D)Ezetimibe"], "prompt": "A 40-year-old woman schedules an appointment for a routine medical check-up. She admits to being careless about her health, but is motivated to improve. She is working with a personal trainer at the gym and is following a weight reduction diet plan. Despite a 20 kg (44 lb) weight loss over the last year, she still feels that she is fat. She was a frequent binge drinker, but now she has reduced her alcohol consumption to a single glass of wine with dinner and an occasional beer on the weekend. She also has a 15 pack-year smoking history, but quit 6 months ago after she developed a cough and shortness of breath that later improved. She admits to trying various recreational drugs in the past. On her last visit, she was started on rosuvastatin for an elevated cholesterol level. She is sexually active with her partner and they have 2 children. She is uncertain about her family history as she was raised in foster care. The vital signs include: pulse 80/min, respirations 16/min, and blood pressure 122/80 mm Hg. The physical examination reveals a visibly overweight woman with a body mass index (BMI) of 34 kg/m2. The remainder of the examination yields no significant findings. An electrocardiogram (ECG) and chest X-ray are both normal. Lab tests show the following:\nSerum glucose (fasting) 95 mg/dL\n    Serum electrolytes:\nSodium 140 mEq/L\nPotassium 3.8 mEq/L\nChloride 101 mEq/L\nSerum creatinine 0.8 mg/dL\nBlood urea nitrogen 10 mg/dL\nCholesterol, total 180 mg/dL\nHDL-cholesterol 42 mg/dL\nLDL-cholesterol 70 mg/dL\nTriglycerides 365 mg/dL\n    Urinalysis:  \nGlucose negative\nKetones negative\nLeucocytes negative\nNitrites negative\nRBC negative\nCasts negative\nWhich medication would most likely further improve her lipid profile?A)Niacin\nB)Orlistat\nC)Fenofibrate\nD)Ezetimibe", "subject_name": null, "output0": "The correct answer is A)Niacin because this medication would most likely further improve her lipid profile by increasing HDL-cholesterol. The patient has a history of smoking and is currently taking rosuvastatin, which lowers LDL-cholesterol. However, she still has high triglycerides and low HDL-cholesterol, which are risk factors for cardiovascular disease. Niacin, a B vitamin, has been shown to increase HDL-cholesterol and improve lipid profiles in patients with dyslipidemia.\n\n", "output1": "Orlistat is a medication that is primarily used to treat high cholesterol and improve lipid profiles. It works by inhibiting the absorption of dietary fats in the gut, which can help to lower LDL (bad) cholesterol levels. In this case, the patient has a history of smoking and a high BMI, which are both risk factors for cardiovascular disease. Orlistat may be a good option for her because it can help to reduce her LDL cholesterol levels and improve her overall lipid profile.\n\n", "output2": "Fenofibrate is a lipid-lowering medication that is commonly used to treat hypertriglyceridemia and mixed dyslipidemia. In this case, the patient has a high triglyceride level (365 mg/dL) and elevated LDL-cholesterol (70 mg/dL), making her a good candidate for fenofibrate therapy. Additionally, fenofibrate has been shown to improve HDL-cholesterol levels, which is a desirable effect for this patient given her low HDL-cholesterol level (42 mg/dL).\n\n", "output3": "Ezetimibe is a medication that is used to lower cholesterol levels by inhibiting the absorption of dietary cholesterol in the small intestine. It is particularly effective in reducing LDL-cholesterol (the \"bad\" cholesterol) and triglycerides. Given the patient's elevated LDL-cholesterol and triglyceride levels, Ezetimibe would be a good choice to further improve her lipid profile.\n\n"}]